Mustang Bio Provides Updates of MB-107 in the P-I/II study for the Treatment of X-Linked Severe Combined Immunodeficiency
Shots:
- The interim results from the P-I/II study evaluates MB-107 in 23 newly diagnosed infants aged ≤2yrs. with XSCID
- The results showed that all patients are alive at 2.6yr. median follow-up without evidence of malignant transformation at a median age of 3mos. & experienced complete hematopoietic recovery, transduced autologous bone marrow CD34+ cells with a median VCN of 0.81/cell & median CD34+ cell dosage of 9.61x106/kg
- Patients also received busulfan at a dose of 22 mg*hr/L before cell infusion & was well tolerated, 15 patients were able to discontinue IV immunoglobulin & 14 have successfully immunized. The company plans to initiate the P-II trial of MB-107 with an expected IND filing in H2’22
Ref: Globe Newswire | Image: Mustang Bio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
